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Abstract
Background: Little is known about contextual factors that predict long-term mortality following HIV testing in
resource-limited settings. We evaluated the impact of contextual factors on 5-year mortality among HIV-infected
and HIV-uninfected individuals in Durban, South Africa.
Methods: We used data from the Sizanani trial (NCT01188941) in which adults (≥18y) were enrolled prior to HIV
testing at 4 outpatient sites. We ascertained vital status via the South African National Population Register. We used
random survival forests to identify the most influential predictors of time to death and incorporated these into a
Cox model that included age, gender, HIV status, CD4 count, healthcare usage, health facility type, mental health,
and self-identified barriers to care (i.e., service delivery, financial, logistical, structural and perceived health).
Results: Among 4816 participants, 39% were HIV-infected. Median age was 31y and 49% were female. 380 of 2508
with survival information (15%) died during median follow-up of 5.8y. For both HIV-infected and HIV-uninfected
participants, each additional barrier domain increased the HR of dying by 11% (HR 1.11, 95% CI 1.05–1.18). Every 10-
point increase in mental health score decreased the HR by 7% (HR 0.93, 95% CI 0.89–0.97). The hazard ratio (HR) for
death of HIV-infected versus HIV-uninfected varied by age: HR of 6.59 (95% CI: 4.79–9.06) at age 20 dropping to a
HR of 1.13 (95% CI: 0.86–1.48) at age 60.
Conclusions: Independent of serostatus, more self-identified barrier domains and poorer mental health increased
mortality risk. Additionally, the impact of HIV on mortality was most pronounced in younger persons. These factors
may be used to identify high-risk individuals requiring intensive follow up, regardless of serostatus.
Trial registration: Clinical Trials.gov Identifier NCT01188941. Registered 26 August 2010.
Keywords: HIV infection, Mortality, Predictors of mortality, Barriers to care
Background
South Africa has the largest number of HIV-infected indi-
viduals of any country, with over 7 million people diag-
nosed with HIV and 270,000 new infections in 2016 [1].
People living with HIV (PLWH) who consistently take
ART in sub-Saharan Africa can achieve life expectancies
similar to those who are HIV-uninfected [2, 3]. However,
mortality remains high both before [4, 5] and after ART
initiation because of inconsistent care [6–10]. Despite 86%
of PLWH in South Africa knowing their HIV status, only
56% were on ART, and only 45% were virally suppressed
in 2016 [1]. Thus, accurately ascertaining factors contrib-
uting to long-term mortality risk following HIV-diagnosis
is paramount.
Studies assessing the long-term risk of mortality in
persons living with HIV in sub-Saharan Africa have
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focused on age, gender, and CD4 counts to evaluate pre-
dictors of risk [11–15]. We and others have found, how-
ever, that contextual factors (e.g. barriers to care),
emotional health, social support, and competing needs
at the time of diagnosis, also likely to have an important
effect on survival [16, 17]. In addition, most mortality
studies, including those that have examined social and
contextual factors, have limited analyses to HIV-infected
individuals [7, 18–23]. Little is known about contextual
factors that predict long-term mortality in resource-lim-
ited settings, for both HIV-infected and HIV-uninfected
individuals. By comparing to a concurrently enrolled
HIV-uninfected group of individuals, who share similar
socioeconomic status, we can further our understanding
of what interventions in the outpatient setting may im-
prove outcomes in South Africa regardless of HIV
status.
Our objective was to assess contextual predictors of 5-
year mortality following HIV testing. Research suggests a
strong correlation between mental health, especially de-
pression, and mortality among people with HIV [24, 25]
and other health conditions [26–28]. Research among
PLWH indicates that such associations may be due to a
relationship between depression and immune suppression,
leading to accelerated disease progression [25, 29, 30].
Moreover, in the US, depression interventions have de-
creased mortality risk, including for those with chronic
diseases, suggesting a causal effect [31–34]. Research also
shows strong associations between social support and
mortality in general [35, 36]. Thus, we hypothesized
that poor emotional health and social support at HIV
diagnosis would be associated with higher 5-year mor-




This analysis includes data from the Sizanani Trial
(NCT01188941), a randomized controlled trial that exam-
ined the efficacy of health system navigation and short
messaging service (SMS) reminders on linkage to and re-
tention in HIV/TB care. We enrolled adults prior to HIV
testing at 4 outpatient sites, 2 hospital outpatient depart-
ments (one urban and one semi-rural) and 2 primary
health clinics (semi-rural) in Durban, South Africa from
August 2010–January 2013. This trial is described in detail
elsewhere [16, 37, 38]. Because we did not find efficacy of
the intervention with respect to linkage to HIV care, TB
treatment completion, or 1-year mortality between study
arms, we pooled data from the intervention and control
groups into a single cohort in the current study and
compared them to HIV-uninfected individuals enrolled
concurrently.
Participants
Adults ≥18 years with unknown HIV status presenting
for HIV testing were eligible for enrollment. Study enroll-
ment, consisting of informed consent and a baseline ques-
tionnaire, occurred prior to HIV testing. This allowed for
assessment of contextual factors, emotional health, and
social support prior to knowledge of HIV status.
The study was approved by the McCord Hospital Medical
Research Ethics Committee, St. Mary’s Hospital Research
Ethics Committee, University of KwaZulu- Natal Biomedical
Research Ethics Committee, and Partners Institutional
Review Board (Protocol 2011-P-001195, Boston, MA).
Data elements
Demographics and CD4 count data
We asked participants to provide demographic informa-
tion including: age, gender, relationship status, and hours
worked outside the home. We collected baseline CD4
count data from medical records for those who were HIV-
infected; missing data is discussed in the Additional file 1.
Healthcare access
We assessed healthcare access using four questions that
determined how difficult it might be for a patient to
reach the site. We collected data on mode of transporta-
tion (public, private, or other) and distance to clinic.
Transportation variables were grouped into two categor-
ies – public transport (bus, taxi) or other (including pri-
vate and other).
Healthcare utilization
We assessed self-reported healthcare utilization in the
year prior to enrollment, including visits to a commu-
nity health worker, local clinic, hospital, or private
doctor. The total utilization was grouped into three
categories: > 5 times, 3–5 times, 1–2 times, did not use
healthcare in prior year. We also asked about number
of visits to a traditional healer.
Health behavior
We asked participants whether they had tested for HIV
prior to enrollment. We assessed self-reported compet-
ing needs at enrollment, by asking if, in the past 6
months, they had ever gone without healthcare because
they needed money for basic needs, or if they had gone
without basic needs because they needed money for
healthcare [39, 40].
Self-perceived barriers to care
We assessed self-perceived barriers to healthcare in the
6months prior to enrollment using a 12-question instru-
ment modified from the ARTAS-II trial [41]. We grouped
barriers into 5 domains: 1) concerns about service delivery
(waiting time to see a provider, treatment by clinic staff),
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2) financial concerns (ability to afford medication or trans-
portation), 3) perception of personal health (not being sick
enough or being too sick), 4) logistical concerns (unable
to get out of work, responsibilities to care for others), 5)
structural (impaired clinic access due to clinic hours or
transportation difficulties, lack of knowledge about where
to find care). We created a total number of barriers vari-
able by adding up all barriers in all 5 categories for each
participant. We created a similar total number of domains
variable by adding up the total number of domains under
which a participant indicated they had a barrier.
Emotional health and social support
We adapted the 5-item Mental Health Inventory screen-
ing test and calculated a mental health composite (MHC)
score [42]. In addition, we condensed 13 questions about
social support into 4 social support scales (emotional/in-
formational, tangible, positive interaction, and affection-
ate) and calculated the Social Support Index (SSI) from
the Medical Outcomes Study [43]. Separately, we averaged
each scale and converted to a scale from 0 to 100. A
higher number on the scale indicates better emotional
health or social support. An MHC ≤ 52 qualified as a posi-
tive depression screen; an SSI below the sample median
(75) qualified as a lack of social support [44].
Outcome ascertainment
We elicited mortality from the National Population Regis-
ter, which is estimated to incorporate at least 90% of
deaths nationwide [13, 45]. We used South African ID
numbers (SAIDs) obtained at enrollment to match partici-
pants to the National Population Register in November
2017; median follow-up was 5.8 years (IQR 5.2–6.5 years).
Statistical analysis
We provide a summary of our methods here; further de-
tails are in the Additional file 1.
Because a substantial fraction of participants were
missing SAIDs, we used propensity score (PS) weighting
[46] to make the population with SAIDs be representa-
tive of the total group. We estimated the probability of
having a SAID from a logistic regression model separ-
ately for HIV-infected and HIV-uninfected including all
available baseline data, and then used inverse probability
weighting to make the population with SAIDs more rep-
resentative of the total population. To avoid potential
confounding of contextual factors by HIV-status, we
then used an additional propensity score adjustment so
that the HIV-infected and HIV-uninfected were similar.
We used random survival forests [47] on all covariates
listed in Table 1 to inform the development of our survival
model. When the number of variables is comparatively
large, a random forest is useful for variable selection be-
cause it avoids overfitting [48]. We determined variable
importance based on permutation importance and vari-
able depth relative to root node (see Additional file 1).
We used a sequential procedure to select the most
important variables for the survival model. We first
identified the most important of the six domains above
to include, and then selected the most important vari-
able(s) in that domain to include in subsequent model
construction. Variable selection was based on combining
the results from two different statistical approaches.
Demographic characteristics were considered the most
important category to include, and age was identified as
the most important covariate in this category. Gender
was selected a priori to be included [49]. Random sur-
vival forests were then fitted separately to each of the
other five categories of covariates, with age, gender, and
HIV status included in all models. The second most im-
portant category and important covariates within that cat-
egory were selected as described above, and the procedure
repeated until at least one variable was selected from each
category if the category was important. We also evaluated
the most important barriers and domains within the
self-perceived barriers to care category as detailed in
the Additional file 1. Because of the influence of CD4
counts on mortality, we included this in the final model
as well. For the 92 HIV-infected participants (8%) miss-
ing CD4, we used multiple imputation based on gender,
age, health facility type, healthcare use in the past year,
total number of domains, and mental health score CD4
counts. HIV-uninfected participants were assigned a
CD4 count of 775 based on the median CD4 count of
the general population in rural KwaZulu-Natal [50].
We also assessed how the association of health care
utilization with mortality varied over the five-year
period by fitting the model for the first third, second
third, and last third of deaths separately.
We fitted a propensity score-weighted Cox propor-
tional hazards model to the final set of selected covari-
ates. The likelihood ratio test was used to test for
interaction effects between HIV status and other covari-
ates included in the Cox model. We used the integrated
area under the curve (AUC) as the measure of accuracy
for the Cox models [51].
We describe the association of each variable with
death using hazard ratios (HR), 95% confidence inter-
vals, and P-values in the fully adjusted model (incorp-
orating propensity score weighting and CD4 value
imputation), and in simpler models without CD4 value
imputation, without propensity score adjustment, and
without both to assess the robustness of our conclu-
sions. We used two-tailed P-values < 0.05 as a cut-off
for statistical significance. Statistical analyses were
performed with SAS version 9.4 (SAS Institute, Cary,
NC) and “randomForestSRC” in R version 3.4.2 (www.
r-project.org) [52].
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Table 1 Differences between HIV-infected and HIV-uninfected participants at baseline
Overall, n = 4816 HIV-infected, n = 1897 HIV-uninfected, n = 2919 P*
Age, yrs
Median (IQR) 31.0 (24–41) 33.0 (27–41) 28.0 (22–42) < 0.001
Sex, n (%)
Male 2477 [51] 964 (51) 1513 [52] 0.491
Female 2339 [49] 933 (49) 1406 [48]
Marital status, n (%)
Never married 3738 (78) 1535 (81) 2203 (76) < 0.001
Currently married 810 (17) 265 (14) 545 (19)
Divorce/separated/widowed 239 (5) 85 (5) 154 (5)
Education, n (%)
Some high school or greater 4148 (87) 1614 (86) 2534 (87) 0.236
Primary school or less 638 (13) 270 (14) 368 (13)
Mode of transport, n (%)
Public transport (bus, taxi) 2283 [48] 877 (47) 1406 [48] < 0.001
Private transport 1117 [23] 524 (28) 593 (20)
Other 1387 [29] 484 (26) 903 (31)
Distance from clinic, n (%)
Less than 5 km 1177 [25] 352 (19) 825 (28) < 0.001
At least 5 km 3610 (75) 1533 (81) 2077 (72)
Health facility type, n (%)
Primary health clinics 1234 [26] 404 (21) 830 (28) < 0.001
Hospital outpatient departments 3582 (74) 1493 (79) 2089 (72)
Work hours outside home, n (%)
None 2697 [56] 944 (50) 1753 [60] < 0.001
Less than 40 h 603 (13) 318 (17) 285 (10)
40 h or more 1516 [32] 635 (34) 881 (30)
Prior HIV testing, n (%)
Yes 1870 [39] 464 (25) 1406 [48] < 0.001
No 2917 (61) 1421 (75) 1496 [52]
Health care use in prior year, n (%)
None 715 (15) 256 (14) 459 (16) 0.006
1–2 times 1499 [31] 570 (30) 929 (32)
3–5 times 1732 [36] 684 (36) 1048 [36]
> 5 times 841 (18) 375 (20) 466 (16)
Visit to traditional healer in prior year, n (%)
Yes 1567 [33] 708 (38) 859 (30) < 0.001
No 3220 (67) 1177 (62) 2043 (70)
Social support score
Median (IQR) 75 (54–87) 67 (50–83) 75 (60–90) < 0.001
Mental health score
Median (IQR) 64 (56–80) 64 (56–76) 68 (56–84) < 0.001
Reported barriers to healthcare, n (%)
Yes 1809 [38] 830 (44) 979 (34) < 0.001
No 3007 (62) 1067 [56] 1940 (66)
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Results
Overall cohort characteristics
There were 4816 enrollees, of whom 1897 (39%) were
HIV-infected (Table 1). The median age of the entire
cohort was 31 years (IQR: 24–41); 33 years for HIV-in-
fected individuals and 28 years for those HIV-unin-
fected (P < 0.001). Overall, 2339 (49%) were female. The
median CD4 count for those with HIV was 196 (IQR:
73–352). Most participants, 3738 (78%), were never
married; 2283 (48%) used public transport to travel to
the healthcare site and 3582 (74%) underwent HIV test-
ing in an hospital outpatient department versus a pri-
mary health clinic.
Self-reported barriers to care
A higher proportion of HIV-infected participants re-
ported one or more barriers to healthcare compared to
those HIV-uninfected (44% vs. 34%; P < 0.001). Among
those who reported any barriers, HIV-infected partici-
pants also reported more barriers than HIV-uninfected
participants: 4 (IQR: 2–6) vs. 3 (IQR: 1–5; P < 0.001).
Likewise, for those who reported any barriers, the total
number of barriers spanned more domains for HIV-in-
fected participants than for HIV-uninfected individuals:
3 (IQR: 2–4) vs. 2 (IQR: 1–4; P < 0.001). 414 (22%) HIV-
infected participants had gone without healthcare for
money to spend on basic needs (i.e. food, clothing, hous-
ing), whereas only 506 (17%) HIV-uninfected partici-
pants had done so (P < 0.001). Similarly, more HIV-
infected individuals 323 (17%) had gone without basic
needs for money to spend on healthcare compared to
401 (14%) HIV-uninfected participants (P = 0.002).
Patient perception of not being sick enough to seek
care (1059; 22%; Table 2) was the most common individ-
ual barrier reported. Uniformly, a higher proportion of
participants who tested positive for HIV reported experi-
encing each type of barrier to care than those who tested
negative; all differences were statistically significant. The
largest discrepancy between HIV-infected and HIV-
uninfected individuals was for waiting too long to see a
nurse or doctor: 506 (27%) of HIV-infected participants
reported this barrier, while only 510 (18%) of HIV-unin-
fected individuals did (P < 0.001).
The most commonly identified barrier domain was pa-
tient perception of personal health, with 1247 (26%) of
participants experiencing a barrier in this category. Across
barrier domains, service delivery showed the largest differ-
ence between HIV-infected and HIV-uninfected partici-
pants: 566 (30%) HIV-infected participants identified a
service delivery barrier, compared to 586 (20%) HIV-unin-
fected participants (P < 0.001). HIV-infected individuals ex-
perienced significantly higher burdens of self-identified
barriers across all domains.
Balance after propensity score adjustment for estimating
impact of HIV-infection on mortality
Of 4816 enrollees, only 1154 of HIV-infected (61%) and
1354 of HIV-uninfected (46%) provided valid SAIDs. As
shown in Additional file 1: Table S1, there were differ-
ences in characteristics between those providing valid
SAIDs and those who did not. As shown in Additional
file 1: Table S2, initial propensity score weighting of
individuals with a valid SAID reduced many of the im-
balances between those with a valid SAID and those
without valid SAID in both the HIV-infected and HIV-
uninfected cohorts. A standard propensity score applied
to these weighted population reduced imbalances be-
tween HIV-infected and HIV-uninfected participants
with valid SAID (Additional file 1: Table S3).
Predictors of mortality
Regardless of HIV status, patients using primary health
clinics, as opposed to those using hospital outpatient de-
partments, had reduced mortality risk (HR: 0.51, 95% CI:
0.38–0.68). A 10-point increase in mental health score
decreased the risk of death by 7% (HR: 0.93; 95% CI:
0.89–0.97). Participants who used healthcare services in
the year before enrollment in the study were at higher
Table 1 Differences between HIV-infected and HIV-uninfected participants at baseline (Continued)
Overall, n = 4816 HIV-infected, n = 1897 HIV-uninfected, n = 2919 P*
Number of barriers for participants reporting barriers
Median (IQR) 3 (2–6) 4 (2–6) 3 (1–5) < 0.001
Number of barrier domains for participants reporting barriers
Median (IQR) 3 (1–4) 3 (2–4) 2 (1–4) < 0.001
Gone without healthcare for basic needs, n (%)
Yes 920 (19) 414 (22) 506 (17) < 0.001
No 3896 (81) 1483 (78) 2413 (83)
Gone without basic needs for healthcare, n (%)
Yes 724 (15) 323 (17) 401 (14) 0.002
No 4092 (85) 1574 (83) 2518 (86)
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risk of dying, with risk increasing as healthcare use in-
creased (> 5 times, HR: 2.34, 95% CI: 1.75–3.12; 3–5
times, HR: 1.86, 95% CI: 1.42–2.44, 1–2 times, HR: 1.53,
95% CI: 1.15–2.02 compared to no use in the past year).
The effect of health care utilization on mortality was re-
duced over time, showing the most substantial effect in
the first third (125 deaths, first 3 months, P < 0.001) a
smaller but still significant effect in the second third
(130 deaths, months 4–21, P < 0.001) of deaths and mar-
ginal impact in the last third of deaths (125 deaths,
month 22 and later, P = 0.07).
There was a significant interaction of HIV-status with
age (HR: 0.63, 95% CI: 0.56–0.70, P < 0.001 for each 10-
year increase in age). Each additional 10 years of life in-
creased the risk of death by 94% for HIV-uninfected par-
ticipants (HR: 1.94, 95% CI: 1.78–2.11), but only by 22%
(HR: 1.22, 95% CI: 1.13–1.31; P < 0.001) for HIV-infected
participants. As shown in Fig. 1, the HR for HIV-in-
fected individuals compared to HIV-uninfected individ-
uals varied from 6.59 (95% CI: 4.79–9.06) at age 20
down to 1.13 (95% CI: 0.86–1.48) at age 60. Sensitivity
analyses showed that results were robust to the modeling
assumptions with HR for HIV-infection ranging from 6.59
to 7.24 at age 20 and 1.13 to 1.29 at age 60; model details
in Table 3.
After adjusting for the HIV x age interaction, there
was some evidence for an interaction of HIV-status with
number of domains, with the mortality risk for HIV-un-
infected individuals increasing by 23% (HR: 1.23, 95% CI:
1.14–1.32) for each additional domain, but more slowly for
HIV-infected individuals 7% (HR: 1.07, 95% CI: 1.02–1.13;
P = 0.002) There was also some evidence that the increased
hazard for males was lower for HIV-infected men (HR:
1.38, 95% CI: 1.16–1.65) then for HIV-uninfected men (HR:
2.18, 95% CI: 1.64–2.89; P = 0.007). Results for HIV-in-
fected and HIV-uninfected individuals separately are re-
ported in Additional file 1: Table S4.
The integrated AUC for the overall Cox regression
model was 0.755. A similar Cox model was fitted separ-
ately to the HIV-uninfected and HIV-infected partici-
pants with HIV status removed (and CD4 value also
removed from the HIV-uninfected population). The
model fit was better for HIV-uninfected compared to H
IV-infected participants (AUC 0.837 vs. 0.687).
Discussion
Among 2503 participants with valid SAIDs and complete
data enrolled at 4 outpatient sites in Durban, South
Africa between 2010 and 2013, more self-identified
barrier domains and poorer mental health increase 5-
year mortality risk, regardless of HIV status. For every
10-point decrease in mental health score, indicating
poorer mental health, 5-year mortality increased by
7%. For each additional self-identified barrier domain
5-year mortality increased by 12%. There was some
evidence for an interaction between HIV status and
risk of 5-year mortality based on number of reported
domains. A higher proportion of HIV-infected partici-
pants reported self-identified barriers across every do-
main when compared to HIV-uninfected participants.
Table 2 Differences in barriers between HIV-infected and HIV-uninfected participants at baseline
Overall, n = 4816 HIV-infected, n = 1897 HIV-uninfected, n = 2919 P*
Barrier domain reported, n (%)
Service delivery 1152 [24] 566 (30) 586 (20) < 0.001
Too long to see nurse/MD 1016 [21] 506 (27) 510 (18) < 0.001
Not treated with respect 179 (4) 93 (5) 86 (3) 0.002
Financial 831 (17) 423 (22) 408 (14) < 0.001
Cost of transport 731 (15) 377 (20) 354 (12) < 0.001
Cost of medication 760 (16) 392 (21) 368 (13) < 0.001
Personal Health 1247 [26] 596 (31) 651 (22) < 0.001
Not sick enough 1059 [22] 503 (27) 556 (19) < 0.001
Too sick 433 (9) 244 (13) 189 (7) < 0.001
Logistical 656 (14) 334 (18) 322 (11) < 0.001
Could not get off work 382 (8) 213 (11) 169 (6) < 0.001
Taking care of someone else 371 (8) 182 (10) 189 (7) < 0.001
Structural 1110 [23] 540 (29) 570 (20) < 0.001
Did not know where to find care 398 (8) 181 (10) 217 (8) 0.033
Difficult hours 778 (16) 402 (21) 376 (13) < 0.001
Language barrier 231 (5) 112 (6) 119 (4) 0.014
Transport 688 (14) 353 (19) 335 (12) < 0.001
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Additionally, increased healthcare use in the prior
year contributed to increased hazard of death for both
HIV-infected and HIV-uninfected individuals. Moreover,
those who were HIV-infected had a 4-fold increase in
hazard of death during follow-up compared to HIV-un-
infected participants at age 31. These results were ro-
bust when analyzed across multiple model variations.
This study highlights that barriers to care negatively affect
survival regardless of HIV status. HIV-infected individuals
reported experiencing significantly more barriers than HIV-
uninfected individuals. This could be related to HIV-in-
fected participants having fewer resources as significantly
more HIV-infected participants also reported more com-
peting needs than their HIV-uninfected counterparts.
Among both HIV-infected and HIV-uninfected individuals,
perception of personal health, service delivery, and struc-
tural barriers were the most frequently reported barrier
domains. Within those domains, both HIV-infected and
HIV-uninfected participants most commonly reported
waiting too long to see a nurse or doctor or not feeling sick
enough to seek care as barriers. Recent studies suggest that
improvements in clinic operations, including standardizing
staff workloads and patient flow, introducing triage, and in-
creasing staff size might help shorten wait times in low-
and middle-income settings [53, 54]. We and others have
found that in sub-Saharan African settings, participants
often feel as though they are not sick enough to seek care
[16, 55] or avoid seeking care when they do not feel ill for
fear that treatment will make them feel worse [56]. Efforts
to improve clinic operations and to promote seeking
routine care may improve long-term mortality in both
HIV-infected and HIV-uninfected individuals.
We found that poor mental health also decreased sur-
vival regardless of HIV status. Instituting mental health
screening not only during HIV testing but also during
routine healthcare appointments could allow providers
to identify patients with poor mental health and connect
them to additional resources. We and others have found
that depressive symptoms are common among HIV-in-
fected patients in sub-Saharan Africa and are correlated
with decreased likelihoods of obtaining a CD4 count or
taking ART [57, 58]. In this study, we used the 5-item
Mental Health Inventory screening test; this short survey
may be feasible to include in routine healthcare visits.
On the other hand, social support was not shown to
affect 5-year mortality risk. This may be because we did
not measure social support in the form of social integra-
tion, which has been shown to be most predictive of
mortality [35, 36].
Despite continued efforts to diagnose and link individuals
to HIV care in South Africa, HIV-infected individuals re-
main at substantially increased risk for long-term mortality
when compared to their HIV-uninfected counterparts at
the same study sites and with similar socioeconomic status.
A recent study reported similar findings in Botswana com-
paring a population-based sample of HIV-infected and -un-
infected individuals [59]. Other studies have evaluated
long-term mortality risk in HIV-infected individuals in sub-
Saharan Africa [11–15], and a few have examined the im-
pact of individual level contextual factors [16, 17]. Unlike
Fig. 1 5-year mortality risk among HIV-infected participants varies by age. Hazard ratio is calculated from the primary model, which includes both
two-stage propensity score adjustment and multiple imputation of CD4 values in the HIV-infected population
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previous studies, however, the present study evaluated
HIV-infected and HIV-uninfected individuals and found
that some factors previously found to be associated with
long-term mortality risk in HIV-infected cohorts, are also
risk factors for HIV-uninfected individuals.
This work should be considered in the context of sev-
eral limitations. We did not adjust for data on ART use
in this model; however, CD4 count was an eligibility cri-
terion for starting ART during the study period and was
included in the model. We did not collect data on other
health-related comorbidities for either HIV-infected or
HIV-uninfected participants; it is possible that those
who reported more barriers to care may have also had
higher rates of comorbid conditions. We also may
underestimate the effects of mental health on mortality
because we did not consider psychotic symptoms, which
have been associated with an even higher relative risk of
mortality compared to anxiety and depression [60].
Healthcare use in the prior year may be on the causal
pathway to mortality, however, we felt this variable was
an important predictor of time to death. We found that
the effect of healthcare use in the prior year on mortality
was reduced over time and may be a stronger predictor
of early mortality than later mortality. The model results
did not change qualitatively when this variable was
removed (data not shown). In addition, only 52% of the
participants provided a valid SAID number for death
registry cross-matching and there were significant differ-
ences between those with and without a valid SAID.
Though we used propensity scores, we were unable to
fully adjust for these differences. Lastly, the methods used
to determine predictors of mortality in this study could
not be readily used in a clinical setting. In addition to
directly addressing those characteristics identified as pre-
dictive of mortality, it is necessary to develop predictive
instruments, for both HIV-infected and HIV-uninfected
individuals, that can be implemented in patient care
settings to identify at risk patients.
Conclusions
HIV infection remains a significant predictor of 5-year
mortality in Durban, South Africa. However, additional
screening for all patients can be used to help identify at
risk individuals who may require additional healthcare
interventions. While HIV-infected patients carry a higher
burden of self-identified barriers to care than their HIV-
uninfected counterparts, the effects of those barriers on
mortality risk is not significantly different between HIV-
infected and HIV-uninfected individuals. Similarly, while
HIV-infected participants reported worse mental health
than HIV-uninfected participants, poor mental health
increased mortality risk for both groups. Interventions are
needed that address both clinic-level barriers to care,
such as long wait times, as well as patient-level barriers,
including efforts to modify beliefs about the risks of
HIV treatment, the benefits of seeking care when feeling
healthy, and routine mental health monitoring. Such tar-
geted interventions could improve health outcomes for
high-risk individuals. Many structural and logistical barriers
can be recognized early, i.e. at the first clinic visit, and could
identify patients that may require more intensive follow-up.
Both alleviation of barriers that pose increased mortality
risks and development of tools to identify high-risk patients
in clinical settings could significantly improve outcomes for
HIV-infected and HIV-uninfected individuals.
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